NCT00607035View on ClinicalTrials.gov

The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)

PHASE4CompletedINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

May 31, 2008

Conditions

Hypertension

Interventions

DRUG

Olmesartan medoxomil ＋Azelnidipine

The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.

DRUG

Olmesartan medoxomil + Hydrochlorothiazide

The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.

Trial Locations (1)

Unknown

Jichi Medical University School of Medicine, Tochigi

All Listed Sponsors

lead

Jichi Medical University

OTHER

NCT00607035 - The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE) | Biotech Hunter | Biotech Hunter